Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × Tetrodotoxin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 2

Sponsor

Conditions

Pain 2 Neoplasms 2

Interventions

Paclitaxel 19 Dexamethasone 16 Bevacizumab 16 Oxaliplatin 14 Docetaxel 14 Cyclophosphamide 12 Capecitabine 12 Gemcitabine 11 Sorafenib 10 Leucovorin 10 Fluorouracil 10 Carboplatin 10 Epoetin Alfa 9 pembrolizumab 8 Pemetrexed 8 Fentanyl 8 venetoclax 7 atezolizumab 7 Prednisone 7 Drug Therapy 7 Doxorubicin 7 Rivaroxaban 6 Ondansetron 6 Morphine 6 Irinotecan 6 Denosumab 6 Cisplatin 6 Tranexamic Acid 5 Sodium Chloride 5 Rituximab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00725114 2014-07-09

TEC-006

Wex Pharmaceuticals Inc.

Phase 3 Completed

Neoplasms, Pain

NCT00726011 2012-10-24

TEC-006OL

Wex Pharmaceuticals Inc.

Phase 3 Completed

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡